Net margin is calculated as Net Income divided by its Revenue. Celon Pharma's Net Income for the
three
months ended in Mar. 2026 was €37.62 Mil. Celon Pharma's Revenue for the
three
months ended in Mar. 2026 was €13.17 Mil. Therefore, Celon Pharma's net margin for the quarter that ended in Mar. 2026 was 285.61%.
The historical rank and industry rank for Celon Pharma's Net Margin % or its related term are showing as below:
FRA:8RP'
s Net Margin % Range Over the Past 10 Years
Min: -24.26 Med: -0.68 Max: 68
Current: 68
FRA:8RP's Net Margin % is ranked better than 98.32% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs FRA:8RP: 68.00
Celon Pharma (FRA:8RP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Celon Pharma Net Margin % Related Terms
Celon Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8RP vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (FRA:8RP) has a Net Margin % of 285.61% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #16 out of 954 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Celon Pharma's Net Margin % too high?
Celon Pharma's current Net Margin % is 285.61%. The Drug Manufacturers industry median Net Margin % is 5.64. Celon Pharma's value of 285.61% is 4968.5% above this industry median. Based on the distribution chart, Celon Pharma ranks #16 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #16 out of 954 companies for Net Margin %. This places Celon Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Celon Pharma's value of 285.61% is 4968.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Net Margin % of 285.61% is 4968.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Net Margin % is 285.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (FRA:8RP) has a current Net Margin % of 285.61%. The stock's GF Value™ is €5.11, compared to a current price of €4.39 — trading 14.1% below its estimated fair value. The current Net Margin % is 285.61% and 4968.5% above the Drug Manufacturers industry median of 5.64. Celon Pharma's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Celon Pharma (FRA:8RP), the current Net Margin % is 285.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (FRA:8RP) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of €4.39 is trading 14.1% below its estimated GF Value™ of €5.11.
Key valuation signals for FRA:8RP:
Net Margin %: 285.61%
GF Value™: €5.11 vs. price of €4.39 (14.1% below fair value)
Industry Position: 4968.5% above the Drug Manufacturers median (#16 of 954)
No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
13GF Score
Get the complete analysis for FRA:8RP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8RP has been successfully added to your 
